Sight Sciences, Inc.
NNASDAQ:SGHTCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Paul Badawi
- Full Time Employees
- 186
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 4040 Campbell Avenue Menlo Park CA United States 94025
- IPO Date
- Jul 15, 2021
- CIK
- 0001531177
- Website
- sightsciences.com
- Similar Companies
- Business
- Sight Sciences, Inc. (SGHT) develops and commercializes ophthalmic medical devices focused on surgical and nonsurgical technologies for treating prevalent eye diseases including glaucoma and dry eye; its core products comprise the OMNI Surgical System, a minimally invasive glaucoma surgery (MIGS) device indicated for canaloplasty and trabeculotomy to target multiple outflow pathway resistance points, and the TearCare System, an office-based therapy addressing meibomian gland dysfunction as the root cause of dry eye disease; additional offerings include the SION Surgical System for enhanced goniotomy procedures. The company operates primarily in two segments, Surgical Glaucoma and Dry Eye, targeting ophthalmologists, optometrists, and specialized eye care clinics across the United States with a direct sales force supported by clinical education; it generates revenue through device sales and procedure-related royalties while maintaining outsourced manufacturing for flexibility. Founded in 2011 and headquartered in Menlo Park, California, Sight Sciences continues to invest heavily in research and development, with 2023 expenditures reaching $24.7 million to advance MIGS and dry eye innovations amid a competitive landscape featuring players like Glaukos and Alcon. Recent developments include the closing of a senior secured credit facility of up to $65 million with Hercules Capital in May 2024 to bolster its balance sheet and strategic execution, alongside reporting third-quarter 2025 financial results that prompted an upward revision to full-year 2025 revenue guidance, reflecting sustained procedural adoption and market expansion.
Company News
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Why Is Sight Sciences Stock Gaining Thursday?
Sight Sciences, Inc. (NASDAQ:SGHT) Stock Has Consensus Price Target of $8.38
Sight Sciences: Signs Of Progress, But Plenty Of Work Remains
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Sight Sciences (NASDAQ:SGHT) Hits New 1-Year High – Should You Buy?
Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. Purchases New Shares in Sight Sciences, Inc. $SGHT
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences Q2 Earnings Call Highlights
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Sight Sciences Reports Second Quarter 2026 Financial Results
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026